Skip to main content
. 2023 Sep 28;6(1):30–39. doi: 10.1016/j.cjco.2023.09.016

Table 3.

Differences in the DASH score associated with each additional BP-lowering medication class among the 915 included participants with MetS-associated high BP, after stratification by key characteristics

Stratification β coefficient (95% CI) associated with each additional BP-lowering medication class P value P value for interaction
Gender
 Women –0.24 (–0.68, 0.20) 0.29 0.24
 Men 0.12 (–0.29, 0.53) 0.57
Age
 Men: < 50 years
Women: < 60 years
–0.72 (–1.24, –0.19) 0.007 0.001
 Men: ≥ 50 years
Women: ≥ 60 years
0.32 (–0.05, 0.69) 0.09
Education level
 High school or less 0.07 (–0.48, 0.63) 0.79 0.61
 College or university –0.10 (–0.45, 0.26) 0.60
Annual household income
 < $50,000 –0.17 (–0.65, 0.30) 0.47 0.52
 ≥ $50,000 0.03 (–0.36, 0.42) 0.89
Body mass index
 < 30 kg/m2 –0.13 (–0.57, 0.32) 0.58 0.55
 ≥ 30 kg/m2 0.06 (–0.35, 0.47) 0.78
Smoking status
 Never –0.08 (–0.59, 0.43) 0.77 0.98
 Past –0.04 (–0.45, 0.37) 0.85
 Current 0.02 (–0.86, 0.89) 0.97
Self-reported history of BP cholesterol
 No 0.09 (–0.29, 0.47) 0.63 0.23
 Yes –0.28 (–0.78, 0.21) 0.26
Framingham risk score
 Low (< 10%) –0.70 (–1.31, –0.09) 0.02 0.05
 Moderate (10%-19%) 0.00 (–0.45, 0.45) 0.99
 High (≥ 20%) 0.30 (–0.24, 0.84) 0.28

BMI, body mass index; BP, blood pressure; CI, confidence interval; DASH, Dietary Approaches to Stop Hypertension; MetS, metabolic syndrome.

Data are presented as β coefficient (95% confidence interval), in DASH points, associated with each additional BP-lowering medication class (continuous variable). Models were adjusted for sex/gender (men, women), age (years), annual household income (< $10,000; $10,000-$24,999; $25,000-$49,999; $50,000-$74,999; $75,000-$99,999; $100,000-$149,999; $150,000-$199,999; > $200,000), BMI (kg/m2), smoking status (never/ever/current), alcohol consumption (grams per day), energy intake (kcal per day), physical activity level (low/moderate/high), and self-reported history of high blood cholesterol (yes/no).